.Charles Baum, M.D., Ph.D., that looked after Mirati Therapies' $ 5.8 billion sale to Bristol Myers Squibb in 2013, is taking the helm of youthful biotech Terremoto Biosciences.Baum's "substantial adventure in medicine development, and also proven record earlier high-impact medications, will definitely be instrumental," outbound CEO Peter Thompson, M.D., claimed in a July 25 release. Thompson will maintain his chair as board chairperson..Baum, an experienced physician-scientist, was actually the creator, head of state and also chief executive officer of oncology-focused Mirati. Before that, he aided build cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Right now, Baum will serve as CEO at Terremoto, a firm creating small particles to target disease-causing healthy proteins-- like those located in harmful tumor cells-- using covalent connects. Existing therapies that use covalent bonds mostly target the amino acid cysteine. However, of the twenty amino acids that comprise proteins, cysteine is actually the minimum popular. Terremoto is actually instead targeting one of the essential amino acids, amino acid lysine, which is found in nearly all proteins.Through targeting amino acid lysine and various other amino acids, Terremoto intends to manage formerly undruggable illness as well as develop first-in-class medications..The biotech, located in South San Francisco, raised $75 million in set A financing in 2022. A little greater than a year eventually, the biotech greater than multiplied that variety in a $175 million set B.